Meeting
2023 ASCO Genitourinary Cancers Symposium
Extended follow-up results from the CheckMate 274 trial.
Presenter
Matt D. Galsky, MD, FASCO
Icahn School of Medicine at Mount Sinai
Disclaimer
This material on this page is ©2024 American Society of Clinical Oncology, all rights reserved. Licensing available upon request. For more information, please contact licensing@asco.org
Videos & Slides Details
Session Type
Oral Abstract Session
Session Title
Oral Abstract Session B: Urothelial Carcinoma
Track
Urothelial Carcinoma
Sub Track
Therapeutics
Clinical Trial Registration Number
NCT02632409
Citation
J Clin Oncol 41, 2023 (suppl 6; abstr LBA443)
DOI
10.1200/JCO.2023.41.6_suppl.LBA443
Abstract #
LBA443
Abstract Disclosures
Similar Videos & Slides
Videos & Slides
2022 ASCO Annual Meeting
Results for patients with muscle-invasive bladder cancer (MIBC) in the CheckMate 274 trial.
Speaker: Alfred Witjes, MD, PhD
Videos & Slides
2022 ASCO Genitourinary Cancers Symposium
Analysis of disease-free survival in CheckMate 274 by PD-L1 combined positive score and tumor proportion score.
Speaker: Matt D. Galsky, MD, FASCO
Videos & Slides
2021 Genitourinary Cancers Symposium
First results from the phase 3 CheckMate 274 trial of adjuvant nivolumab vs placebo in patients who underwent radical surgery for high-risk muscle-invasive urothelial carcinoma (MIUC).
Speaker: Dean F. Bajorin, MD, FACP, FASCO
Speaker: Timothy Jerome Moynihan, MD